David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California, USA.
Retina. 2011 Jun;31(6):1028-35. doi: 10.1097/IAE.0b013e318217ffde.
To investigate elevated intraocular pressures (IOP) (defined by a measurement >25 mmHg at a follow-up visit) after an intravitreal injection of anti-vascular endothelial growth factor agents for age-related macular degeneration.
Retrospective review of medical records.
A total of 127 patients (155 eyes) received an intravitreal injection of anti-vascular endothelial growth factor agents (bevacizumab, ranibizumab, or pegaptanib) ranging from 1 to 39 injections for more than a period of 30 to 1759 days. Among this population, 12 patients (14 eyes; 9.4%) developed elevated IOP >25 mmHg. Of these, 7 patients (5.5%) developed sustained elevated IOP (IOP >25 mmHg on 2 separate visits requiring glaucoma medication or surgery), of which 8 eyes required topical medications and 1 eye underwent glaucoma surgery. Mean IOP of injected eyes receiving intravitreal injection was 15.2 ± 2.4 mmHg, and the mean IOP was 14.9 ± 2.6 mmHg for noninjected eyes. Among eyes that had elevated IOPs, there was no association with injection frequency, number of injections, or anti-vascular endothelial growth factor agent used.
Elevated IOP, sustained or unsustained, after intravitreal injection is not uncommon. No association with patient demographics or injection history was identified in the authors' study population.
研究接受抗血管内皮生长因子（VEGF）药物玻璃体内注射治疗年龄相关性黄斑变性后，眼内压（IOP）升高（随访时测量值＞25mmHg）的情况。
回顾性病历分析。
共 127 例（155 只眼）患者接受了 1 至 39 次不等的抗 VEGF 药物玻璃体内注射治疗（贝伐单抗、雷珠单抗或康柏西普），治疗时间超过 30 至 1759 天。在这部分人群中，有 12 例（14 只眼；9.4%）出现 IOP 升高＞25mmHg。其中，7 例（5.5%）患者的 IOP 持续升高（2 次随访时 IOP＞25mmHg，需要使用降眼压药物或手术治疗），其中 8 只眼需要局部药物治疗，1 只眼接受了青光眼手术。接受玻璃体内注射的患眼平均 IOP 为 15.2±2.4mmHg，未接受注射的患眼平均 IOP 为 14.9±2.6mmHg。在出现 IOP 升高的眼中，与注射频率、注射次数或所使用的抗 VEGF 药物之间均无相关性。
玻璃体内注射后 IOP 升高（持续或不持续）并不少见。在作者的研究人群中，未发现与患者人口统计学特征或注射史相关的因素。
